Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 22, 2009

Lundbeck to Evaluate to-BBB's Technology for Delivering CNS-Disease Antibodies across the Blood-Brain Barrier

  • Lundbeck is tapping into the brain-drug delivery expertise of Netherlands-based to-BBB through a collaboration focused on delivering antibodies against central nervous system diseases. The research will focus on the use of to-BBB's G-Technology, which uses liposomes coated with glutathione-conjugated PEG to mediate the safe targeting and enhanced delivery of drugs directly across the blood-brain barrier.

    The collaboration with Lundbeck is the fourth for to-BBB within the last few months. In November the company signed a research collaboration with Genzyme to evaluate the use of the G-Technology as a delivery vehicle for biologics against neurodegenerative diseases.

    In September to-BBB teamed up with MedImmune to investigate the safe delivery of drugs to the brain using the G-Technology. In June the company announced a collaboration with researchers at The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL) focused on developing a potential new therapy for brain tumors.

    To-BBB's lead in-house candidate is G-Technology formulated doxorubicin, 2B3-101, which is expected to start clinical trials during the second half of 2010.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »